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ABT-737 promotes tBid mitochondrial accumulation to
enhance TRAIL-induced apoptosis in glioblastoma cells
S Cristofanon
1,2 and S Fulda*
,1,2
To search for novel strategies to enhance the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis pathways in glioblastoma, we used the B-cell lymphoma 2/Bcl2-like 2-inhibitor ABT-737. Here we report that ABT-737
and TRAIL cooperate to induce apoptosis in several glioblastoma cell lines in a highly synergistic manner (combination index
o0.1). Interestingly, the concerted action of ABT-737 and TRAIL to trigger the accumulation of truncated Bid (tBid) at
mitochondrial membranes is identiﬁed as a key underlying mechanism. ABT-737 and TRAIL cooperate to cleave BH3-interacting
domain death agonist (Bid) into its active fragment tBid, leading to increased accumulation of tBid at mitochondrial membranes.
Coinciding with tBid accumulation, the activation of Bcl2-associated X protein (Bax), loss of mitochondrial membrane potential,
release of cytochrome-c and second mitochondria-derived activator of caspase (Smac) into the cytosol and caspase activation
are strongly increased in cotreated cells. Of note, knockdown of Bid signiﬁcantly decreases ABT-737- and TRAIL-mediated Bax
activation and apoptosis. Also, caspase-3 silencing reduces ABT-737- and TRAIL-induced Bid cleavage and apoptosis,
indicating that a caspase-3-driven, mitochondrial feedback loop contributes to Bid processing. Importantly, ABT-737 profoundly
enhances TRAIL-triggered apoptosis in primary cultured glioblastoma cells derived from tumor material, underlining the clinical
relevance. Also, ABT-737 acts in concert with TRAIL to suppress tumor growth in an in vivo glioblastoma model. In conclusion,
the rational combination of ABT-737 and TRAIL cooperates to trigger tBid mitochondrial accumulation and apoptosis.
This approach presents a promising strategy for targeting the apoptosis pathways in glioblastoma, which warrants further
investigation.
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Glioblastoma is the most frequent primary malignant brain
tumor with a very poor prognosis, thus calling for novel
treatment strategies.
1,2 Evasion of apoptosis (programmed
cell death) is a hallmark of glioblastoma that promotes
tumorigenesis and progression, as well as treatment
resistance.
3,4 The two key signaling pathways of apoptosis
comprise the extrinsic (death receptor) pathway and the
intrinsic (mitochondrial) pathway.
3 In the death receptor
pathway, the ligation of receptors of the tumor necrosis factor
(TNF) superfamily, such as TNF-related apoptosis-inducing
ligand(TRAIL) receptors, results inthe formation ofthe death-
inducing signaling complex (DISC) and activation of caspase-8,
which subsequently leads to activation of effector caspases
such as caspase-3.
5 In the mitochondrial pathway, the
permeabilization of the outer mitochondrial membrane leads
to the release of cytochrome-c and second mitochondria-
derived activator of caspase (Smac) from the mitochondrial
intermembrane space into the cytosol, resulting in activation
of caspase-9 and -3.
6 The release of mitochondrial proteins is
tightly controlled by pro- and antiapoptotic proteins of the
B-cell lymphoma 2 (Bcl-2) family.
7 Both pathways are linked
by the Bcl-2 family protein BH3-interacting domain death
agonist (Bid), which is cleaved by caspase-8 into truncated
Bid (tBid) that in turn translocates to mitochondrial mem-
branes to initiate mitochondrial outer-membrane permeabili-
zation.
8 In addition, caspase-3 can process Bid into tBid,
thereby promoting a feedback ampliﬁcation loop to cause
further mitochondrial perturbations.
9
Proapoptotic TRAIL receptor agonists represent promising
therapeutics in oncology, given their ability to trigger the cell’s
intrinsic death program, preferentially, in cancer versus
normal cells, and are currently being evaluated in early
clinical trials.
10,11 However, primary or acquired resistance of
glioblastoma toward TRAIL calls for alternative approaches to
restore TRAIL sensitivity. Resistance to TRAIL may be
caused by increased expression of antiapoptotic molecules
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12Upregulationof
the prosurvival proteins Bcl-2 and Bcl2-like 2 (Bcl-XL)
and downregulation of Bcl2-associated X protein (Bax) have
been described in recurrent glioblastoma before treat-
ment.
13,14 Because the ratio of pro- versus antiapoptotic
Bcl-2 proteins is considered to have an important role in
regulating the susceptibility of cancer cells to undergo
apoptosis, shifting this balance towards apoptosis provides
a powerful means to initiate apoptosis.
7 To antagonize
prosurvival Bcl-2 proteins, Bcl-2 homology domain 3 (BH3)-
mimetics, that is, small molecules that have structural or
functional similarities to BH3-only proteins, were recently
developed and are presently under preclinical and clinical
evaluation.
6 One of the most advanced and well-character-
ized BH3 mimetics is ABT-737, which predominantly binds to
Bcl-2, Bcl-XL and Bcl-w, while having low afﬁnity to myeloid
cell leukemia sequence 1.
15 Recently, ABT-737 was reported
to exert antitumor activity as single agent in glioblastoma cells
invitro.
16Tosearchfornovelstrategiestotargettheapoptosis
signaling pathways for the treatment of glioblastoma,
we investigated the combination of ABT-737 and TRAIL to
target the intrinsic and extrinsic pathways of apoptosis in the
present study.
Results
ABT-737 enhances TRAIL-induced antitumor activity
against glioblastoma in vitro and in vivo. To examine
whether the neutralization of antiapoptotic Bcl-2 family
proteins can enhance TRAIL-induced cell death, we selected
ﬁve glioblastoma cell lines (i.e., U87MG, U118MG, T98G,
U138MG and A172), which are heterogeneous for p53 and
PTEN status (Supplementary Table 1), two key signaling
components that are often altered in glioblastoma.
17 A
survey of pro- and antiapoptotic Bcl-2 proteins revealed that
they are expressed in these cell lines at variable levels
(Supplementary Figure 1a). Importantly, ABT-737 enhanced
TRAIL-mediated reduction of cell viability in several
glioblastoma cell lines in a highly synergistic manner as
calculated by combination index (CI) (Figure 1a, Supple-
mentary Table 2a). To validate these ﬁndings in clinical tumor
material, we extended our studies to primary cultured
glioblastoma samples obtained from surgical specimens.
Of note, ABT-737 and TRAIL synergistically reduced cell
viability of primary cultured glioblastoma cells (Figure 1b,
Supplementary Table 2b). By comparison, ABT-737 and
TRAIL did not signiﬁcantly reduce cell viability of human
ﬁbroblasts at concentrations that synergized to reduce cell
viability of glioblastoma cells (Supplementary Figure 1b).
To investigate whether ABT-737 enhances TRAIL-induced
cell death not only in monolayer cultures in vitro but also in a
three-dimensional tumor model in vivo, we used the chor-
ioallantoic membrane (CAM) model, an established in vivo
tumor model, for example, for anticancer drug testing.
18–20 To
this end, U87MG glioblastoma cells were seeded on the CAM
of chicken embryos, allowed to form tumors, and were treated
with ABT-737 and/or TRAIL for three consecutive days.
Importantly, the combination treatment with ABT-737 and
TRAILcooperatedtosuppresstumorgrowth,whereasneither
ABT-737 nor TRAIL as single agent inhibited tumor growth
(Figures 1c and d). Together, these ﬁndings demonstrate that
ABT-737 enhances TRAIL-induced antitumor activity against
glioblastoma in vitro and in vivo.
ABT-737 cooperates with TRAIL to trigger caspase
activation and caspase-dependent apoptosis. To eluci-
date the molecular mechanism of the synergistic interaction
of TRAIL and ABT-737, we focused our study on U87MG and
U118MG cells, as the synergism was most pronounced in
these cell lines (Supplementary Table 2a). Analysis of DNA
fragmentation as a characteristic feature of apoptotic cell
death showed that ABT-737 signiﬁcantly enhanced TRAIL-
induced DNA fragmentation (Figure 2a). Moreover, ABT-737
promoted activation of caspase-8, -9 and -3 as indicated by
increased processing of the proenzyme forms into active
caspase fragments, that is, caspase-8 into p43/41 and p18
fragments, caspase-9 into p37/35 fragments and caspase-3
into p17/12 fragments (Figure 2b). Addition of the broad-
range caspase-inhibitor zVAD.fmk completely rescued
loss of cell viability by TRAIL and ABT-737 (Figure 2c).
To investigate whether caspase inhibition has an effect on
long-term survival, we also assessed colony formation. Of
note, zVAD.fmk signiﬁcantly inhibited TRAIL/ABT-737-
mediated suppression of colony formation (Figure 2d,
Supplementary Figure 2). Together, this set of experiments
demonstrates that ABT-737 and TRAIL cooperate to trigger
activation of caspases and caspase-dependent apoptosis.
No effect of ABT-737 on TRAIL receptor (TRAIL-R) 1/2
expression, TRAIL-induced DISC formation or complex II
assembly. Next, we systematically investigated whether
ABT-737 enhances signaling via the extrinsic pathway
of apoptosis. To this end, we assessed surface expression
of agonistic TRAIL receptors by ﬂow cytometry, because the
cooperative action of ABT-737 and TRAIL has previously
been attributed to NF-kB (nuclear factor of kappa light
polypeptide gene enhancer in B cell)-mediated upregulation
of TRAIL-R2.
21 U87MG and U118MG cells displayed low
TRAIL-R1 levels in line with a recent study reporting frequent
epigenetic silencing of TRAIL-R1 in glioblastoma.
22
Treatment with ABT-737 had no effect on TRAIL-R1 or -R2
expression, whereas exposure to TRAIL or TRAIL plus
ABT-737 resulted in reduced TRAIL-R2 surface expression
(Supplementary Figure 3a), consistent with its internalization
upon ligand binding.
23 Also, ectopic expression of IkBa
superrepressor did not alter the sensitivity of glioblastoma
cells to ABT-737- and TRAIL-induced apoptosis
(Supplementary Figure 3b), indicating that the synergistic
induction of apoptosis by ABT-737 and TRAIL in glioblas-
toma cells is not due to NF-kB-mediated upregulation of
TRAIL-R2 as reported in other cancer cell lines.
21 Further-
more, analysis of the DISC in response to TRAIL receptor
ligation revealed no alterations in the recruitment of Fas-
associated death domain (FADD) or caspase-8 to activated
TRAIL receptors in the presence or absence of ABT-737
(Supplementary Figure 3c). In addition, the aggregation of
FADD, caspase-8 and receptor-interacting serine-threonine
kinase 1 into the cytosolic complex II upon TRAIL stimulation
was not affected by the addition of ABT-737 (Supplementary
Figure 3d). Together, this set of data indicates that
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Cell Death and DiseaseABT-737-mediated sensitization of glioblastoma cells toward
TRAIL is not due to changes in TRAIL receptor expression,
formation of the TRAIL DISC or complex II assembly.
ABT-737 and TRAIL cooperate to promote Bid cleavage,
accumulation of tBid at mitochondria, Bax activation
and mitochondrial outer membrane permeabilization.
To explore whether the synergistic induction of apoptosis by
ABT-737 and TRAIL involves a cross-talk between the
extrinsic and the intrinsic apoptosis pathways, we analyzed
the effect of the caspase-8-selective inhibitor zIETD.fmk on
mitochondrial outer membrane permeabilization. Interest-
ingly, the addition of zIETD.fmk attenuated Bax activation
(Figure 3a) and signiﬁcantly reduced loss of mitochondrial
membrane potential in cells treated with ABT-737 and TRAIL
(Figure 3b). These ﬁndings indicate that caspase-8 activity
n
o
 
A
B
T
-
7
3
7
A
B
T
-
7
3
7
no TRAIL TRAIL
0
1
2
3
4
5
6
T
u
m
o
r
 
a
r
e
a
 
(
m
m
2
)
ABT-737
TRAIL
-
-
+
-+
-+
+
0
20
40
60
80
100
120
140
025
TRAIL [ng/ml]
%
 
v
i
a
b
i
l
i
t
y
0
20
40
60
80
100
120
140
025
TRAIL [ng/ml]
%
 
v
i
a
b
i
l
i
t
y
A172
T98G
0
20
40
60
80
100
120
140
05 1 0
TRAIL [ng/ml]
%
 
v
i
a
b
i
l
i
t
y
ABT 0μM ABT 5μM
U118MG
0
20
40
60
80
100
120
025
TRAIL [ng/ml]
%
 
v
i
a
b
i
l
i
t
y
ABT 0μM ABT 5μM
U87MG
0
20
40
60
80
100
120
01 0 2 0
TRAIL [ng/ml]
%
 
v
i
a
b
i
l
i
t
y
ABT 0μM ABT 5μM
U138MG
GB2 GB1
0
20
40
60
80
100
120
140
%
 
v
i
a
b
i
l
i
t
y
0
20
40
60
80
100
120
%
 
v
i
a
b
i
l
i
t
y
ABT-737
TRAIL
-
-
+
-+
-+
+
ABT-737
TRAIL
-
-
+
-+
-+
+
ABT 0μM ABT 10μM
ABT 0μM ABT 10μM
Figure 1 ABT-737 enhances TRAIL-induced antitumor activity against glioblastoma cells in vitro and in vivo. (a) Glioblastoma cells were treated with indicated
concentrations of ABT-737 and/or TRAIL for 24h. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assayand is expressed
as percentage of untreated controls. Data represent meanþS.E.M. of three independent experiments performed in triplicate (*Po0.005 and **Po0.001, comparing
samples in the presence and absence of ABT-737). (b) Primary glioblastoma cells were treated with 5mM (GB1) or 10mM (GB2) ABT-737 and/or 2ng/ml (GB1) or 10ng/ml
(GB2)TRAIL for 24h. Cell viabilitywas determinedby MTTassayand isexpressedas percentage of untreated controls.Data representmeanþS.E.M.of three independent
experiments performed in triplicate (**Po0.001). (c and d) U87MG cells were seeded on the CAM of chicken embryos and treated with 2.5mM ABT-737 and/or 10ng/ml
TRAIL for 3 days. Tumor growth was analyzed using hematoxylin and eosin-stained parafﬁn sections of the CAM as described in Materials and Methods. Tumor area as
percentageoftheuntreatedcontrolgroup(c)andrepresentativepicturesofhematoxylinandeosin-stainedsectionsoftheCAM(d)areshown.DatarepresentmeanþS.E.M.
of 10 samples per group (
*Po0.005). Similar results were obtained in two independent experiments
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Figure 2 ABT-737synergizeswithTRAILtotriggercaspase-dependentapoptosis.(a)U87MG(leftpanel)andU118MG(rightpanel)cellsweretreatedforindicatedtimes
with 5ng/ml (U87MG) or 10ng/ml (U118MG) TRAIL and/or 5mM ABT-737. Apoptosis was determined by FACS analysis of DNA fragmentation of propidium iodide-stained
nuclei. Data represent mean±S.E.M. of three independent experiments performed in triplicate (**Po0.001). (b) U87MG (left panel) and U118MG (right panel) cells were
treated for indicated times with 5ng/ml (U87MG) or 10ng/ml (U118MG) TRAIL and/or 5mM ABT-737. Caspase activation was analyzed by western blotting; arrowheads
indicatecaspasecleavagefragments.Arepresentativeexperimentofthreeindependentexperimentsisshown.(c)U87MG(leftpanel)andU118MG(rightpanel)cellstreated
for 24h with 5ng/ml (U87MG) or 10ng/ml (U118MG) TRAIL, 5mM ABT-737 and/or 20mM zVAD.fmk. Cell viability was determined by MTT assay and is expressed as
percentage of untreated controls.Data representmeanþS.E.M. of three independentexperiments performed in triplicate.(d) U87MGcells were treatedfor 12h with 5ng/ml
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Cell Death and Diseasecontributes to mitochondrial outer membrane permeabiliza-
tion upon the combined treatment with ABT-737 and TRAIL.
As activation of caspase-8 can cause cleavage of Bid into
tBid, which in turn translocates to the mitochondria to initiate
mitochondrial perturbations,
8 we next examined whether Bid
may link the extrinsic and intrinsic pathways in this model of
apoptosis. Importantly, we detected tBid, the active cleavage
product of Bid, predominately in cells that were cotreated with
ABT-737 and TRAIL, whereas little Bid cleavage was
observed upon treatment with either compound alone
(Figure 4a). Because tBid inserts into mitochondrial mem-
branes upon its cleavage,
8 we then analyzed tBid levels in the
mitochondrial fraction. Of note, ABT-737 and TRAIL acted in
concert to trigger the accumulation of tBid at mitochondrial
membranes (Figure 4b). As mitochondrial carrier 2 (Mtch2)
has recently been reported to facilitate the recruitment of tBid
to mitochondria,
24 we examined whether the combination of
TRAIL and ABT-737 causes an increase in Mtch2 expression.
However, no upregulation of Mtch2 expression was found
upon treatment with TRAIL, ABT-737 or the combination
(Supplementary Figure 4).
AstBidtriggerstheconformationalchangeofBaxthatleads
to Bax activation,
8 we then assessed Bax activation by
immunoprecipitating Bax via an active conformation-speciﬁc
antibody. Importantly, ABT-737 profoundly enhanced TRAIL-
induced activation of Bax (Figure 4c). Furthermore, ABT-737
cooperated with TRAIL to induce loss of mitochondrial
membrane potential and the release of cytochrome-c and
Smac from mitochondria into the cytosol (Figures 4d and e).
These results show that ABT-737 and TRAIL cooperate to
trigger mitochondrial translocation of tBid, Bax activation and
mitochondrial outer membrane permeabilization.
To explore whether tBid accumulation at the mitochondria
and mitochondrial outer membrane permeabilization are
general features of the synergism of ABT-737 and TRAIL,
we extended our studies to additional glioblastoma cell lines.
Similarly, increased translocation of tBid to mitochondrial
membranes and enhanced loss of mitochondrial membrane
potential upon cotreatment with ABT-737 and TRAIL were
found in several glioblastoma cell lines (Supplementary
Figure 5), in which ABT-737 and TRAIL synergistically
induced apoptosis (Figure 1a, Supplementary Table 2a).
ThisdemonstratesthatmitochondrialtranslocationoftBidand
mitochondrial outer membrane permeabilization are common
features of the synergistic induction of apoptosis by ABT-737
and TRAIL in glioblastoma cell lines.
Bid is a critical mediator of ABT-737- and TRAIL-induced
apoptosis. To investigate the functional relevance of Bid
for the synergistic induction of apoptosis by ABT-737
and TRAIL, we silenced Bid by RNA interference (RNAi)
(Figure 5a). Importantly, knockdown of Bid reduced activa-
tion of Bax upon treatment with ABT-737 and TRAIL
(Figure 5b). Also, silencing of Bid signiﬁcantly decreased
ABT-737- and TRAIL-induced apoptosis and loss of cell
viability (Figures 5c and d). To determine whether Bid
knockdown simply delays cell death or affects long-term
survival upon treatment with ABT-737 and TRAIL, we
performed colony assays. Of note, Bid silencing signiﬁ-
cantly rescued the ABT-737/TRAIL-mediated suppression of
colony formation (Figure 5e).
In addition to Bid, we also knocked down Bcl2-like 11
(Bim), another Bcl-2 family protein previously implicated in
regulating sensitivity to ABT-737.
25 Notably, silencing of Bim
in U118G cells did not affect ABT-737- and TRAIL-induced
loss of cell viability (Supplementary Figure 6a). Moreover,
because of the limited amount of Bim protein in U118G cells
(Supplementary Figure 1a), we silenced Bid and Bim in T98G
cells, a glioblastoma cell line that harbors high levels of both
proteins (Supplementary Figure 1a). Similarly, knockdown
of Bid, but not of Bim, signiﬁcantly reduced ABT-737- and
TRAIL-induced apoptosis in T98G cells (Supplementary
Figure 6b). These ﬁndings demonstrate that Bid is an
important mediator of the synergistic induction of apoptosis
by ABT-737 and TRAIL.
Stabilization of tBid and caspase-3 ampliﬁcation loop
contribute to ABT-737- and TRAIL-induced apoptosis.
As tBid has a short half-life due to proteasomal degradation,
we hypothesized that ABT-737 might prevent the degrada-
tion of tBid and increase its half-life by promoting tBid
insertion into mitochondrial membranes via inhibition of
Bcl-2/Bcl-xL. To address this question, we treated T98G
cells for 2h with TRAIL in the absence or presence of ABT-
737 to induce the conversion of Bid to its tBid form. After this
stimulation, cells were washed, the caspase-inhibitor
zVAD.fmk was added to the culture medium to prevent
further tBid cleavage and tBid levels were monitored over
time. Interestingly, the addition of ABT-737 to TRAIL resulted
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Figure 3 Caspase-8 contributes to activation of the intrinsic apoptosis pathway
upon treatment with ABT-737 and TRAIL. (a) U87MG (left panel) and U118MG
(right panel) cells were treated for 4h with 5ng/ml (U87MG) or 10ng/ml (U118MG)
TRAIL and 5mM ABT-737 in the presence or absence of 20mM caspase-8 inhibitor
(zIETD.fmk). Bax conformational change was determined by immunoprecipitation
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U118MG (right panel) cells were treated for 6h with 5ng/ml (U87MG) or 10ng/ml
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triplicate is shown (*Po0.005)
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Cell Death and Diseasein a longer half-life of tBid compared with treatment with
TRAIL alone (Figure 6a).
In addition to caspase-8, caspase-3 has also been reported
to cleave Bid into tBid.
9 As we observed that ABT-737
substantially enhanced TRAIL-induced caspase-3 activation
(Figure 2b), as well as proteolytic processing of Bid
(Figure 4a), we asked whether caspase-3 contributes to Bid
cleavage via a feedback ampliﬁcation loop. To address this
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10ng/ml (U118MG) TRAIL and/or 5mM ABT-737. Expression of cytochrome-c and Smac in cytosolic and mitochondrial fractions was determined by western blot analysis. CoxIV
and a-tubulin served as purity and loading controls of the fractions. In (a–c and e), representative experiments of three independent experiments are shown
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Cell Death and Diseasequestion, we silenced caspase-3 (Figure 6b) and then
monitored Bid processing upon treatment with ABT-737 and
TRAIL. Interestingly, caspase-3 knockdown attenuated clea-
vage of Bid into tBid (Figure 6b), decreased ABT-737- and
TRAIL-induced apoptosis (Figure 6c), increased cell viability
upon combination treatment (Supplementary Figure 7) and
suppressed colony formation (Figure 6d). This indicates that
caspase-3 contributes to proteolytic processing of Bid in a
feedback ampliﬁcation loop.
Discussion
In this study, we demonstrate that the simultaneous activation
oftheextrinsicandintrinsicapoptosispathwaysbyTRAILand
ABT-737, respectively, presents a promising approach to
synergistically trigger apoptosis in glioblastoma cells in vitro
and in vivo. This conclusion is supported by several individual
pieces of evidence. First, ABT-737 enhances TRAIL-induced
apoptosis in a highly synergistic manner as conﬁrmed by
calculation of CI. Second, synergistic cytotoxicity of ABT-737
and TRAIL occurs in several glioblastoma cell lines,
underscoring the general relevance of this ﬁnding. Third, the
combination treatment with ABT-737 and TRAIL proved to be
effective to suppress tumor growth both in vitro and in an
in vivo glioblastoma model. Fourth, this synergism not only
occurs in established glioblastoma cell lines but also in
primary glioblastoma cultures derived from tumor samples,
underlining the clinical relevance of these results.
Furthermore, the novelty of the study resides in the identi-
ﬁcation of a new molecular mechanism, underlying the
synergistic interaction of ABT-737 and TRAIL (Suppleme-
ntary Figure 8). Accordingly, we demonstrate that ABT-737
and TRAIL act in concert to promote the cleavage of Bid into
tBid. Although TRAIL triggers cleavage of Bid into tBid by
activating caspase-8, ABT-737 facilitates the accumulation of
tBid at mitochondrial membranes by neutralizing Bcl-2 and
Bcl-XL. This enhances the cross-talk between the extrinsic
and the intrinsic apoptosis pathways and initiates a mitochon-
drial ampliﬁcation loop, resulting in increased Bax activation,
loss of mitochondrial membrane potential, the release
of cytochrome-c and Smac from mitochondria and caspase-
dependent apoptosis. Also, the combination treatment of
ABT-737 andTRAILcontributestoBidcleavageinafeedback
loopviaincreasedcaspase-3activity,assilencingofcaspase-
3 attenuates processing of Bid into tBid. The critical role of
Bid for the synergistic interaction of ABT-737 and TRAIL is
underscored by knockdown experiments, showing that Bid
silencing also attenuates ABT-737- and TRAIL-induced
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Figure 5 Bid is essential for ABT-737 and TRAIL-induced apoptosis. U87MG and U118MG cells were transduced with control vector (shCtrl) or a vector containing two
differentshRNAsequencesagainstBid(shBid_1andshBid_2).(a)ExpressionofBidwasanalyzedbywesternblotting.(b)U87MG(leftpanel)andU118MG(rightpanel)cells
were treated for 4 h with 5ng/ml (U87MG) or 10ng/ml (U118MG) TRAIL and/or 5mM ABT-737. Bax conformational change was determined by IP, Bax expression in lysates
served as control. A representative experiment of three independent experiments is shown. (c) U87MG (left panel) and U118MG (right panel) cells were treated for 24h with
5ng/ml (U87MG)or 10ng/ml (U118MG)TRAIL and/or 5mM ABT-737. Apoptosiswas determinedby FACS analysis of DNA fragmentationof propidiumiodide-stained nuclei.
DatarepresentmeanþS.E.M. of three independentexperiments performed in triplicate(*Po0.005 and**Po0.001). (d)U87MG (left panel)and U118MG(right panel) cells
weretreatedfor24hwith5ng/ml(U87MG)or10ng/ml(U118MG)TRAILand/or5mMABT-737.CellviabilitywasdeterminedbyMTTassayandisexpressedaspercentageof
untreated controls. Data represent meanþS.E.M. of three independent experiments performed in triplicate. (e) U87MG (left panel) and U118MG (right panel) cells were
treatedfor 12hwith 5ng/ml(U87MG)or10ng/ml(U118MG)TRAIL and/or5mM ABT-737.Colonies werestainedwith crystalviolet after18 daysandwerecountedunderthe
microscope. One representative experiment (lower panel) and the percentage of colony numbers compared with untreated control are shown (upper panel). Data represent
meanþS.E.M. of three independent experiments (**Po0.001)
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Cell Death and DiseaseBax activation and apoptosis. Thus, the combination
treatment simultaneously activates the extrinsic and
intrinsic apoptosis pathways and also enhances cross-talks
between both pathways, resulting in synergistic induction of
apoptosis.
A critical role of tBid in the regulation of mitochondrial
outer membrane permeabilization has been shown in a recent
study.
26 Accordingly, tBid was reported to rapidly bind to
mitochondrial membranes, where its BH3 domain facilitates
the insertion of cytosolic Bax into the membrane, leading
to activation and oligomerization of Bax and, subsequently, to
membrane permeabilization.
26 Antiapoptotic Bcl-2 proteins,
such as Bcl-XL, were shown to prevent Bax activation and
mitochondrial outer membrane permeabilization via several
mechanisms, that is, by directly binding to Bax and
by sequestering tBid, thereby preventing Bax activation by
tBid.
26 In addition, Bcl-XL and Bcl-2 were recently found to
stimulate retrotranslocation of Bax from the mitochondria into
the cytoplasm, thereby sustaining Bax in its cytosolic inactive
conformation.
27 Interestingly, this retrotranslocation process
was inhibited by ABT-737, resulting in accumulation of Bax on
the mitochondrial outer membrane, where it acquired its
active conformation.
27 Thus, ABT-737 can increase the levels
ofbothtBidandBaxatthe outermitochondrial membranethat
are free to interact, thereby promoting the ability of tBid to
trigger Bax oligomerization and activation.
Figure 6 Stabilization of tBid and caspase-3 ampliﬁcation loop contributes to ABT-737 and TRAIL-induced apoptosis. (a) T98G cells were treated for 2h with 2ng/ml
TRAIL and 5mM ABT-737 or with 5ng/ml TRAIL. Then, cells were washed three times to remove all residual TRAIL and incubated with 20mM zVAD.fmk for indicated times.
The tBid protein expression was determined by western blotting. One representative experiment is shown, and similar results were obtained in two independent experiments.
(b) U87MG and U118MG cells were transduced with control vector (shCtrl) or a vector containing two different shRNA sequences against Caspase-3 (shC3_1 and shC3_2).
Expression of caspase-3 was analyzed by western blotting. U87MG (left panel) and U118MG (right panel) cells were treated for 4h with 5ng/ml (U87MG) or 10ng/ml
(U118MG) TRAIL and/or 5mM ABT-737. Expression of Bid was analyzed by western blot. a-tubulin served as loading control. A representative experiment of three
independent experiments is shown. (c) U87MG (left panel) and U118MG (right panel) cells were treated for 24h with 5ng/ml (U87MG) or 10ng/ml (U118MG) TRAIL and/or
5mM ABT-737. Apoptosis was determined by FACS analysis of DNA fragmentation of propidium iodide-stained nuclei. Data represent meanþS.E.M. of three independent
experiments performed in triplicate(*Po0.005 and **Po0.001).(d) U87MG (left panel) and U118MG (right panel) cells were treated for 12h with 5ng/ml (U87MG)or 10ng/
ml (U118MG) TRAIL and/or 5mM ABT-737. Colonies were stained with crystal violet after 18 days and were counted under the microscope. One representative experiment
(lower panel) and the percentage of colony numbers compared with untreated control are shown (upper panel). Data represent meanþS.E.M. of three independent
experiments (**Po0.001)
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Cell Death and DiseaseTogether, our ﬁndings provide novel insights into the
synergistic action of ABT-737 and TRAIL compared with
previous studies on other cancers.
21,28 Although Song et al.
21
suggested that NF-kB-mediated increase of TRAIL-R2
accounts for the sensitization to TRAIL by ABT-737,
we observed no differences in TRAIL-R2 surface levels upon
treatment with ABT-737. Also, NF-kB inhibition by over-
expression of IkBa-SR had no effect on ABT-737- and
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Cell Death and DiseaseTRAIL-induced apoptosis of glioblastoma cells in our study.
In pancreatic carcinoma cells, Huang et al.
28 reported
that ABT-737 releases the proapoptotic proteins Bim and
Bcl2-antagonist/killer (Bak) from sequestration by Bcl-XL or
Bcl-2.However,BimandBakareunlikelythekeymediatorsof
ABT-737- and TRAIL-mediated apoptosis in glioblastoma
cells,becausewefoundthatthecombinationtreatmentisalso
effective in glioblastoma cells with low expression levels of
Bim and Bak, for example, in U87MG and U138MG cells.
Together, these ﬁndings suggest that the molecular mechan-
isms underlying the synergism of ABT-737 and TRAIL likely
depend on the tumor and/or cell type. This implies that it is
necessarytoevaluatethecombinationofABT-737andTRAIL
in a given tumor in order to identify the signaling events that
are responsible for the synergistic antitumor activity, thus
underlining the importance of our work.
The translational relevance of our preclinical study is
underscored as follows: This hypothesis-driven evaluation
involves the rational combination of emerging treatment
options for new targets, that is, the Bcl-2-inhibitor ABT-737
and the death receptor ligand TRAIL. Parallel experiments
using primary tumor material highlight the clinical relevance of
the ﬁndings. Importantly, the combination of ABT-737 plus
TRAIL is also active in an in vivo model of glioblastoma.
Thus, these data have important implications for the devel-
opment of novel combination protocols for the treatment of
glioblastoma. A derivative of ABT-737 as well as proapoptotic
TRAIL receptor agonists are currently under evaluation in early
clinical trials,
10,11,29 suggesting that it is in principle feasible
to translate this combination approach of ABT-737 and TRAIL
into clinical testing. In conclusion, this study provides convincing
evidence that ABT-737 in combination with TRAIL presents a
promising novel strategy to trigger the apoptosis pathways in
glioblastoma, which warrants further investigation.
Materials and Methods
Cell culture and reagents. Glioblastoma cell lines were obtained from
ATCC (Manassas, VA, USA). Glioblastoma cell lines and primary cultured
glioblastoma cells were cultured as previously described.
30 The p53 and
PTEN status of glioblastoma cell lines is summarized in Supplementary Table 1.
31
For combination treatment, cells were pretreated with ABT-737 for 1h before TRAIL
was added. ABT-737 was kindly provided by Abbott Laboratories (Abbott Park, IL,
USA), TRAIL was purchased from R&D Systems Inc. (Wiesbaden, Germany) and all
chemicals from Sigma (Deisenhofen, Germany) unless indicated otherwise.
Determination of apoptosis and cell viability. Apoptosis was
determined by ﬂuorescence-activated cell sorting (FACS) analysis (FACScan;
BD Biosciences, Heidelberg, Germany) of DNA fragmentation of propidium
iodide-stained nuclei as previously described.
32 Cell viability was assessed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay according to the
manufacturer’s instructions (Roche Diagnostics, Grenzach, Germany).
Western blot analysis. Western blot analysis was carried out as previously
described
33 using the following antibodies: caspase-8 (Alexis, Gru ¨nberg, Germany);
caspase-3 (Cell Signaling, Beverly, MA, USA); caspase-9 and FADD (BD Biosciences);
Bid (R&D Systems Inc.); Bax NT (Upstate Biotechnology, Lake Placid, NY, USA);
COXIV (Molecular Probes, Life Technologies, Darmstadt, Germany); Bax6A7and
b-actin (Sigma); and goat-anti-mouse IgG, goat-anti-rabbit IgG and donkey-anti-goat
IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) conjugated to horseradish
peroxidase. Enhanced chemiluminescence was used for detection (Amersham
Bioscience, Freiburg, Germany).
Subcellular fractionation. Cytosolic and mitochondrial fractions were
prepared as previously described.
19 Brieﬂy, 3 10
6 cells were harvested and
washed twice in phosphate buffered salt. Pellets were resuspended in cytosolic
lysis buffer (2mM NaH2PO4,1 6m MN a 2HPO4, 150mM NaCl, 500mM sucrose,
1mM ditiotreitolo (DTT), 0.5mg/ml digitonin and protease-inhibitor cocktail) for
5min on ice. Cells were centrifuged for 1min at 14000r.p.m. at 41C. The resulting
supernatant was collected as the cytosolic fraction and the pellet was resuspended
in mitochondrial lysis buffer (30mM Tris HCl, 150mM NaCl, 1% TritonX, 10%
glycerol, 200mM phenylmethylsulfonyl ﬂuoride, 2mM DTT and protease-inhibitor
cocktail) for 2h at 41C. The suspension was then centrifuged at 14000r.p.m. for
20min at 41C. The resulting supernatant was kept as the mitochondrial fraction.
Determination of mitochondrial membrane potential. Tetra-
methylrhodamine ethyl ester (1mg/ml; Sigma) was used to measure the
mitochondrial transmembrane potential. Cells were incubated for 10min at 371C
in the presence of the ﬂuorochrome and immediately analyzed by ﬂow cytometry.
Loss of mitochondria potential is represented by the percentage of cells with
decreased ﬂuorescence.
RNAi-mediated silencing. HEK293T producer cells were transfected with
7.5mg pGIPZ-shRNAmir vector, 12.5mg pCMV-dR8.91 and 1mg pMD2.G using
calcium phosphate transfection. All pGIPZ-shRNAmir vectors were purchased
from Thermo Fisher Scientiﬁc (Waltham, MA, USA): non-silencing control (ShCtrl):
RHS4346, shC3_1: 50-CATGTAATGGTATCTTAAA-30, shC3_2: 50-CCGACAAGC
TTGAATTTAT-30, shBid_1: 50-GCCACTGTTTGGAAATAAA-30 and shBid_2: 50-C
CGTGATGTCTTTCACACA-30. The virus containing supernatant was collected
after 48h and ﬁltered using a 45-mm ﬁlter. U87MG and U118MG cells were
transduced by centrifugation at 1000 g for 1h at room temperature in the
presence of 8mg/ml polybrene and selected for 2 weeks with 1mg/ml puromycin.
Colony formation assay. For colony assay, cells were seeded after 12h of
treatment as single cells (200 cells per well) in six-well plates, and colony
formation was assessed after additional 18 days by crystal violet staining with
0.75% crystal violet, 50% ethanol, 0.25% NaCl and 1.57% formaldehyde.
Immunoprecipitation. Bax activation was determined by immunoprecipita-
tion as previously described.
34 Brieﬂy, cells were lysed in CHAPS lysis buffer
(10mM HEPES, pH 7.4, 150mM NaCl and 1% CHAPS). An amount of 2mg
protein was incubated with 16mg mouse anti-Bax antibody (clone 6A7; Sigma)
overnight at 41C followed by addition of 10ml pan-mouse IgG Dynabeads (Dako,
Hamburg, Germany), incubated for 2h at 41C, washed with CHAPS lysis buffer
and analyzed by western blotting using rabbit anti-BaxNT antibody.
CAM assay. CAM assay was done as described previously.
18 Brieﬂy, 1 10
6
cells were implanted on fertilized chicken eggs on day 8 of incubation and were
treated with 5mM ABT-737 and/or 10ng/ml TRAIL for 3 days, sampled with the
surrounding CAM, ﬁxed in 4% paraformaldehyde, parafﬁn embedded, cut in 5-mm
sections and were analyzed by immunohistochemistry using 1:1 hematoxyline
and 0.5% eosin. Images were digitally recorded at a magniﬁcation of  2 with an
AX70 microscope (Olympus, Center Valley, PA, USA), and tumor areas were
analyzed with ImageJ digital imaging software (NIH, Bethesda, MD, USA).
Statistical analysis. Statistical signiﬁcance was assessed by Student’s t-test
(two-tailed distribution, two-sample, unequal variance). CI was calculated as
described by Chou
35 using CalcuSyn software (Biosoft, Cambridge, UK).
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